Stuart Sprague to Cost-Benefit Analysis
This is a "connection" page, showing publications Stuart Sprague has written about Cost-Benefit Analysis.
Connection Strength
0.058
-
Comparative cost-benefit analyses of paricalcitol and calcitriol in stage 4 chronic kidney disease from the perspective of a health plan. Clin Drug Investig. 2007; 27(2):105-13.
Score: 0.058